Scinai Immunotherapeutics Ltd. has announced a significant private placement aimed at raising approximately $4 million. This funding is crucial for the company as it seeks to enhance its capabilities in the competitive biological products sector. The announcement came through a filing submitted to the SEC on October 15, 2026, detailing the terms of the private placement and the strategic intentions behind it.
Founded in Jerusalem, Scinai Immunotherapeutics is a company focused on developing innovative therapies in the field of immunotherapy. The company operates under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). Scinai is publicly traded on the Nasdaq under the ticker symbol SCNI.
According to the SEC filing, on October 13, 2026, Scinai entered into a Securities Purchase Agreement with an accredited investor. The agreement involves the issuance and sale of 2,458,334 American Depositary Shares (ADSs), each representing 40,000 ordinary shares of the company. Additionally, the company will offer warrants to acquire up to 3,687,501 ADSs at an exercise price of $1.20 per ADS. The combined purchase price for these securities is set at $1.20 per ADS, with the transaction expected to close on or about October 15, 2026, subject to customary closing conditions.
The filing states, "The Company intends to use the net proceeds, together with existing cash resources, to support the expansion of its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline." This strategic move is seen as a way to strengthen Scinai's position in the biological products market, particularly as competition intensifies.
The private placement is indicative of a broader trend within the industry, where companies are increasingly seeking private investments to fund their growth and development initiatives. This trend highlights the ongoing demand for innovative therapies in the biological products sector, as firms strive to meet evolving healthcare needs.
In connection with this private placement, Scinai has also entered into a registration rights agreement with the investor. This agreement requires the company to file a registration statement with the SEC to register the resale of the securities sold in the private placement within fifteen calendar days of the filing date. The company aims to have the registration effective within sixty calendar days.
Furthermore, the filing reveals that A.G.P./Alliance Global Partners acted as the exclusive Placement Agent for the company in this transaction. Scinai has agreed to pay the Placement Agent a cash fee of up to 7% of the gross proceeds from the private placement, along with reimbursement for transaction-related expenses.
As Scinai Immunotherapeutics moves forward with this private placement, the company is poised to leverage the raised funds to enhance its operational capabilities and expand its product offerings. The biological products industry continues to evolve, and Scinai's actions reflect a proactive approach to securing its future in this competitive landscape.
The filing does not specify what happens next beyond the anticipated closing of the private placement. However, with the funds from this transaction, Scinai is expected to make significant strides in its strategic initiatives.